Roivant SciencesROIV
ROIV
About: Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Employees: 908
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
68% more first-time investments, than exits
New positions opened: 67 | Existing positions closed: 40
8% more funds holding
Funds holding: 289 [Q3] → 313 (+24) [Q4]
2% more capital invested
Capital invested by funds: $6.52B [Q3] → $6.65B (+$137M) [Q4]
0.9% more ownership
Funds ownership: 76.36% [Q3] → 77.26% (+0.9%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 17 [Q3] → 17 (+0) [Q4]
9% less repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 102
14% less call options, than puts
Call options by funds: $9.58M | Put options by funds: $11.1M
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$18
77%
upside
Avg. target
$18
77%
upside
High target
$18
77%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Douglas Tsao 17% 1-year accuracy 29 / 171 met price target | 77%upside $18 | Buy Reiterated | 11 Feb 2025 |
Financial journalist opinion
Positive
Investors Business Daily
1 month ago
Roivant, Immunovant Succeed In Phase 3. But There's A Twist — And Shares Tumbled.
Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval. The post Roivant, Immunovant Succeed In Phase 3.
Neutral
GlobeNewsWire
1 month ago
Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported topline results from its Phase 3 study of batoclimab in MG and initial results from Period 1 of its Phase 2b study in CIDP.
Neutral
GlobeNewsWire
1 month ago
Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Believe Montes Archimedes Acquisition (ROIV) Could Rally 60%: Here's is How to Trade
The consensus price target hints at a 60% upside potential for Montes Archimedes Acquisition (ROIV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Neutral
GlobeNewsWire
1 month ago
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
BASEL, Switzerland and VANCOUVER, B.C. and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio (a subsidiary of Roivant Sciences, Ltd. (Nasdaq: ROIV)), and Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on infectious disease, today filed five international lawsuits seeking to enforce patents protecting their innovative LNP technology against Moderna, Inc. and certain affiliates. Together, the enforcement actions target alleged infringing activities in 30 countries.
Positive
Zacks Investment Research
2 months ago
All You Need to Know About Montes Archimedes Acquisition (ROIV) Rating Upgrade to Buy
Montes Archimedes Acquisition (ROIV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Neutral
Seeking Alpha
2 months ago
Roivant Sciences Ltd. (ROIV) Q3 2024 Earnings Call Transcript
Roivant Sciences Ltd. (NASDAQ:ROIV ) Q3 2024 Earnings Conference Call February 10, 2025 8:00 AM ET Company Participants Stephanie Lee - IR Matt Gline - CEO Conference Call Participants David Risinger - Leerink Partners Dennis Ding - Jefferies Yaron Werber - TD Cowen Brian Cheng - JPMorgan Yatin Suneja - Guggenheim Securities Douglas Tsao - H.C.
Positive
The Motley Fool
2 months ago
Roivant Sciences Tops Q3 Expectations
Biopharmaceutical company Roivant Sciences (ROIV 0.18%) reported earnings for the third quarter of 2024 on Monday, Feb. 10, that topped analysts' consensus estimates. Q3 revenue of $9.02 million surpassed estimates of $5 million, reflecting the company's strategic momentum.
Negative
Zacks Investment Research
2 months ago
Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Tops Revenue Estimates
Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.24.
Neutral
GlobeNewsWire
2 months ago
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update
BASEL, Switzerland and LONDON and NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the third quarter ended December 31, 2024, and provided a business update. Brepocitinib to be developed in third indication, cutaneous sarcoidosis (CS), an orphan indication with high unmet need; Phase 2 study initiation expected in second quarter of calendar year with topline data in second half of calendar year 2026 IMVT-1402 development is rapidly progressing with six Investigational New Drug (IND) applications cleared and pivotal studies in Graves' disease (GD) and difficult-to-treat rheumatoid arthritis (D2T RA) initiated Batoclimab topline results from pivotal trial in myasthenia gravis (MG) and initial results from period 1 of trial in chronic inflammatory demyelinating polyneuropathy (CIDP) expected by March 31, 2025 Progress in ongoing LNP litigation, with the summary judgment phase in the Moderna case taking place across the second and third quarters of calendar year 2025 and a jury trial scheduled for September 2025 Roivant reported consolidated cash, cash equivalents, restricted cash and marketable securities of approximately $5.2 billion at December 31, 2024, not including a one-time regulatory milestone of $75 million received in January for the approval of VTAMA in atopic dermatitis and $113 million of external capital raised in Immunovant's January private placement “Roivant has broadened our clinical pipeline with the newly announced trial of brepocitinib in cutaneous sarcoidosis.
Charts implemented using Lightweight Charts™